Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 12, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at 10:15 a.m. Pacific Time.
加利福尼亚州伯林格姆--(美国商业资讯)--2024年11月12日--Innoviva, Inc.（纳斯达克股票代码：INVA）（“Innoviva” 或 “公司”）是一家多元化控股公司，拥有核心特许权使用费组合、名为Innoviva Specialty Therapeutics（“IST”）的领先重症监护和传染病平台以及医疗资产战略投资组合，今天宣布，管理层将参加炉边谈话瑞银全球医疗保健会议将于太平洋时间2024年11月13日星期三上午10点15分在加利福尼亚州帕洛斯维德斯牧场举行。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at . The webcast will be available for replay for 90 days following the event.
可以在公司网站 “投资者关系” 部分的 “活动与演讲” 下观看炉边谈话的网络直播，网址为。网络直播将在活动结束后的90天内重播。
About Innoviva
关于 Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化的控股公司，拥有核心特许权使用费组合、名为Innoviva Specialty Therapeutics（“IST”）的领先重症监护和传染病平台，以及对医疗资产的战略投资组合。Innoviva的特许权使用费投资组合包括与葛兰素史克集团有限公司（“葛兰素史克”）合作的呼吸资产。Innoviva有权从葛兰素史克获得销售RELVAR/BREO ELLIPTA和ANORO ELLIPTA的特许权使用费。Innoviva的其他创新医疗资产包括因收购Entasis Therapeutics而产生的传染病和重症监护资产，包括XACDURO（注射用舒巴坦；注射用度洛巴坦），经批准用于治疗由鲍曼不动杆菌-钙醋复合物敏感菌株引起的医院获得性细菌性肺炎和呼吸机相关细菌性肺炎的成年人，以及正在研究的目前正在开发用于治疗无并发症的淋病的全效佐立氟达辛，拉霍亚制药公司，包括GIAPREZA（血管紧张素II），获准提高患有败血症或其他分布性休克的成人的血压，并批准XERAVA（依拉环素）用于治疗成人复杂的腹腔内感染。
ANORO, RELVAR and BREO are trademarks of the GSK group of companies.
ANORO、RELVAR和BREO是葛兰素史克集团公司的商标。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Innoviva, Inc.
大卫帕蒂
企业传播
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投资者和媒体：
Argot Par
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
资料来源：Innoviva, Inc.
